| Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2-breast cancer (ABCSG-42/AFT-05/BIG-14-13). O Metzger, KV Ballman, M Gnant, M Watson, E Chen, K Tran, P O'Brien, ... Journal of Clinical Oncology 42 (16_suppl), 538-538, 2024 | | 2024 |
| Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity KE Houlahan, A Khan, NF Greenwald, CS Vivas, RB West, M Angelo, ... Science 384 (6699), eadh8697, 2024 | 1 | 2024 |
| Abstract GS03-11: Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity K Houlahan, A Khan, N Greenwald, R West, M Angelo, C Curtis Cancer Research 84 (9_Supplement), GS03-11-GS03-11, 2024 | | 2024 |
| PhyloVelo enhances transcriptomic velocity field mapping using monotonically expressed genes K Wang, L Hou, X Wang, X Zhai, Z Lu, Z Zi, W Zhai, X He, C Curtis, ... Nature Biotechnology 42 (5), 778-789, 2024 | 10 | 2024 |
| Abstract NG01: Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity K Houlahan, A Khan, N Greenwald, C Sotomayor Vivas, RB West, ... Cancer Research 84 (7_Supplement), NG01-NG01, 2024 | | 2024 |
| High-resolution mapping of oncogenic structural changes in osteosarcoma AS Clugston, S Leung, E Fuentes, L Sayles, M Ostrowski, C Wu, C Curtis, ... Cancer Research 84 (6_Supplement), 2860-2860, 2024 | | 2024 |
| Breast cancer genomic architecture contributes to immune escape across metastasis L Mangiante, K Houlahan, CS Vivas, A Adimoelja, S Park, A Khan, ... Cancer Research 84 (6_Supplement), 3931-3931, 2024 | | 2024 |
| The temporal influence of the tumor microenvironment in response to checkpoint blockade NF Greenwald, I Nederlof, H Horlings, M Kok, C Curtis, M Angelo Cancer Research 84 (6_Supplement), 3894-3894, 2024 | | 2024 |
| Multi-ancestral origins of colorectal lesionsMulti-ancestral origins of colorectal lesions RO Schenck, A Khan, A Horning, ED Esplin, D Van Egeren, ... Cancer Research 84 (6_Supplement), 3872-3872, 2024 | | 2024 |
| Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach CR Schott, AL Koehne, LC Sayles, EP Young, C Luck, K Yu, AG Lee, ... Clinical Cancer Research 30 (4), 849-864, 2024 | 1 | 2024 |
| Abstract B008: The polyclonal path towards malignant transformation in familial adenomatous polyposis RO Schenck, A Khan, AM Horning, ED Esplin, HTAN Consortia, ... Cancer Research 84 (3_Supplement_2), B008-B008, 2024 | | 2024 |
| Rampant transcription replication conflict creates therapeutic vulnerability in extrachromosomal DNA containing cancers J Tang, NE Weiser, G Wang, S Chowdhry, EJ Curtis, Y Zhao, ITL Wong, ... bioRxiv, 2024.03. 29.586681, 2024 | | 2024 |
| Systems and Methods for Assessing Mutational Burden of Neoplasms And Associated Treatments Thereof S Tilk, DA Petrov, J Frydman, C Curtis US Patent App. 18/320,148, 2023 | | 2023 |
| Functional screening of amplification outlier oncogenes in organoid models of early tumorigenesis AA Salahudeen, JA Seoane, K Yuki, AT Mah, AR Smith, K Kolahi, M Sean, ... Cell reports 42 (11), 2023 | | 2023 |
| The G1/S transition is promoted by Rb degradation via the E3 ligase UBR5 S Zhang, LF Valenzuela, E Zatulovskiy, L Mangiante, C Curtis, ... bioRxiv, 2023 | 3 | 2023 |
| A microwell platform for high-throughput longitudinal phenotyping and selective retrieval of organoids A Sockell, W Wong, S Longwell, T Vu, K Karlsson, D Mokhtari, J Schaepe, ... Cell systems 14 (9), 764-776. e6, 2023 | 3 | 2023 |
| Serine starvation silences estrogen receptor signaling through histone hypoacetylation AM Li, B He, D Karagiannis, Y Li, H Jiang, P Srinivasan, Y Ramirez, ... Proceedings of the National Academy of Sciences 120 (38), e2302489120, 2023 | 7 | 2023 |
| PhyloVelo enhances transcriptomic velocity field mapping using monotonically expressed genes Z Hu, K Wang, L Hou, X Wang, X Zhai, Z Lu, Z Zi, W Zhai, X He, C Curtis, ... | | 2023 |
| Erratum: Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts (Cancer Cell (2022) 40 (12 … SH Strand, B Rivero-Gutiérrez, KE Houlahan, JA Seoane, LM King, ... Cancer cell 41 (7), 1381, 2023 | | 2023 |
| Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts SH Strand, B Rivero-Gutiérrez, KE Houlahan, JA Seoane, LM King, ... Cancer cell 41 (7), 1381, 2023 | | 2023 |
